WO1996007665A1 - Anthracycline derivatives - Google Patents
Anthracycline derivatives Download PDFInfo
- Publication number
- WO1996007665A1 WO1996007665A1 PCT/EP1995/003480 EP9503480W WO9607665A1 WO 1996007665 A1 WO1996007665 A1 WO 1996007665A1 EP 9503480 W EP9503480 W EP 9503480W WO 9607665 A1 WO9607665 A1 WO 9607665A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- group
- hydrogen
- anthracycline
- alkyl
- Prior art date
Links
- 0 CC1(C)O*CO1 Chemical compound CC1(C)O*CO1 0.000 description 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
Definitions
- the present invention relates to treating
- amyloidosis to novel compounds for such treatment, to processes for their preparation and to pharmaceutical compositions containing them.
- amyloidosis cell death and loss of tissue function appears to be of relevance for different types of disorders including neurodegenerative disorders. Therefore, the prevention of amyloid formation and/or the induction of amyloid degradation can be an important therapeutic tool for all pathological disorders associated with amyloidosis including AL amyloidosis and neurodegenerative disorders of the Alzheimer's type.
- the present invention provides the use in the manufacture of a medicament for use in the treatment of amyloidosis of an anthracycline of formula A
- R 1 represents:
- alkyl C 5 -C 6 cycloalkyl or CH 2 Ph, with the
- phenyl (Ph) ring optionally substituted by 1, 2 or 3 substituents selected from F, CI, Br, C 1 -C 6 alkyl, C 1 -C 6 alkoxy and CF 3 ; or - a group of formula OSO 2 R 5 in which R 5 is C 1 -C 6 alkyl or Ph optionally substituted by 1, 2 or 3
- R 2 represents hydrogen, hydroxy or OR 4 wherein R 4 is as above defined;
- R 3 represents hydrogen, methyl or a group of formula YCH 2 R 6 in which Y is CO, CH 2 , CHOH or a group of formula
- R 7 and R 8 are each independently selected from:
- R 9 and R 10 are each independently selected from hydrogen, C 1 -C 12 alkyl, C 2 -C 12 alkenyl or phenyl optionally substituted by one or more, for example 1, 2 or 3, substituents selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, F, Br, CI, CF 3 , OH, NH 2 or CN,
- COR 9 COOR, or OH, wherein R 9 is as above defined, d) phenyl C 1 -C 4 alkyl or phenyl C 2 -C 4 alkenyl optionally substituted on the phenyl ring by one or more, for example 1, 2 or 3, substituents selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, F, Br, CI, CF 3 , OH, NH 2 or CN, and e) COR 9 , COOR 9 , CONR 9 R 10 , COCH 2 NR 9 R 10 , CONR 9 COOR 10 or SO 2 R 9 in which R 9 and R 10 are as defined above, or
- alkyl C 2 -C 6 alkenyl or phenyl optionally substituted by one or more, for example 1, 2 or 3, substituents selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, F, Br, CI, CF 3 , OH, NH 2 or CN, and
- a pyrrolidino, piperidino or tetrahydropyridino ring optionally substituted by OH, NH 2 , COOH, COOR,or
- R 9 and R 10 are as above defined, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or phenyl optionally substituted by one or more, for example 1, 2 or 3 , substituents selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, F, Br, CI,
- D is a group of formula COOR 9 or CONR 7 R 8 in which R 7 , R 8 and R 9 are as above defined; and X represents a sugar residue of formula X1 or X2
- R 11 and R 12 are both hydrogen or one of R 11 and R 12 is hydrogen and the other is F, CI, Br or I;
- R 7 , R 8 and R 9 are as above defined and p is 0 or 1;
- R 14 and R 15 represent hydrogen, or one of R 14 and R 15 is hydrogen and the other is OH, F, Cl, Br, I or a group of formula OSO 2 R 5 wherein R 5 is as above defined;
- R 16 represents CH 2 OH or R 13 as above defined;
- R 17 represents F, Cl, Br, I or a group of formula
- R 14 and R 15 do not represent a residue in which both R 14 and R 15 are hydrogen atoms or one of R 14 or R 15 is hydroxy and R 13 is amino when R 3 is a group of formula YCH 3 , COCH 2 NR 7 'R 8 ', COCH 2 R' 4 or YCH 2 OH, wherein Y is as above defined, R' 4 is phenyl, benzyl, C 1 -C 6 alkyl or C 5 -C 6 cycloalkyl, R' 7 R' 8 are each independently hydrogen, C 1 -C 12 alkanoyl or, taken together, form a morpholino, piperazino or piperidino residue;
- - X1 does not represent a residue in which R 11 and R 12 are both hydrogen atoms, R 13 is amino and R 14 is iodine when R 1 is methoxy, R 2 is hydroxy and R 3 represents COCH 2 OH.
- Each alkyl, alkoxy, or alkenyl group may be a straight chain or branched chain group.
- a C 1 -C 12 alkyl group is preferably a C 1 -C 6 alkyl group.
- a C 1 -C 6 alkyl group is preferably a C 1 -C 4 alkyl group.
- a C 1 - C 6 alkyl group is preferably methyl, ethyl, n-propyl, iso- propyl, n-butyl, t-butyl, sec-butyl or n-pentyl.
- a C 1 -C 4 alkyl group is preferably methyl, ethyl, n-propyl, iso- propyl, n-butyl, t-butyl or sec-butyl.
- a C 3 -C 6 cycloalkyl group is preferably a C 5 -C 6
- a C 5 -C 6 cycloalkyl group is preferably cyclopentyl or cyclohexyl.
- a peptidyl residue may comprise up to 6, for example 1 to 4, amino acid residues.
- Suitable residues are Gly, Ala, Phe, Leu, Gly-Phe, Leu-Gly, Val-Ala, Phe-Ala, Leu- Phe, Phe-Leu-Gly, Phe-Phe-Leu, Leu-Leu-Gly, Phe-Tyr-Ala, Phe-Gly-Phe, Phe-Leu-Gly-Phe, Gly-Phe-Leu-Gly, Gly-Phe-Leu-Gly.
- R 1 is preferably hydrogen or methoxy.
- R 2 is preferably hydroxy.
- R 3 is preferably a group of formula YCH 2 R 6 in which Y is CO or a group of formula:
- R 6 is:
- R 7 and R 8 are independently selected from: a') hydrogen,
- D is a group of formula CONR 7 R 8 wherein NR 7 R 8 is as above defined; and X represents a sugar residue of formula X1
- R 11 and R- 2 represent hydrogen of one of R 11 or R 12 is hydrogen and the other is I;
- R 14 and R 15 represent h ydrogen or one or R 14 or R 15 is hydrogen and the other is OH, I or OSO 2 CH 3 .
- the present invention provides the salts of those compounds of formula A that have salt-forming groups, especially the salts of the compounds having a carboxylic group, a basic group (e.g. an amino group).
- the salts are especially physiologically tolerable salts, for example alkali metal and alkaline earth metal salt (e.g. sodium, potassium, lithium, calcium and
- magnesium salts ammonium salts, salts with an appropriate organic amine or amino acid (e.g. arginine, procaine salts) and the addition salts formed with suitable organic or inorganic acids, for example hydrochloric acid, sulfuric acid, carboxylic acid and sulfonic organic acids (e.g.
- the present invention encompasses all the possible stereoisomers as well as their racemic or optically active mixtures.
- R 1 OCH 3
- R 2 OH
- R 3 COCH 2 NHCH 2 [C 6 H 3 (OCH 3 ) 2 ]
- A6 13-deoxo-13-ethylenedioxy-14-[p-dimethylaminocarbonyl- amino)phenyloxy]-3'-N-trifluoroacetyl-4'-iododaunomycin
- R 1 OCH 3
- R 2 OH
- R 3 C(OCH 2 CH 2 O) CH 2 O-C 6 H 4
- R 13 NHCOCF 3
- R 14 I
- R 1 OCH 3
- R 2 OH
- R 3 COCH 2 NHCH 2 [C 6 H 3 (OCH 2 ) 2 ]
- R 1 OCH 3
- R 2 OH
- R 3 COCH 2 NHCH 2 [C 6 H 5 (OCH 3 ) 2 ]
- R 13 NHCOCF 3
- R 14 OSO 2 CH 3
- A14 14-N-(morpholino)-3'-N-phthaloyl-4'-methanesulfonatedaunomycin
- the compounds of formula A may be prepared, depending on the nature of the substituents, starting from known anthracyclines by appropriate chemical modifications of the aglycone or the sugar moiety or both part of the molecule, or by coupling anthracyclinones with sugars.
- Processes for preparing compounds of formula A and pharmaceutically acceptable salts thereof are as follows: (i) A preferred process for the preparation of compounds of formula A wherein R 3 is a group of formula COCH 2 NR 7 R 8 , wherein R 7 and R 8 are as above defined with the proviso that R 7 and R 8 do not represent the groups COR 9 , CONR 9 R 10 ,
- CONR 9 COOR 10 or SO 2 R 9 in which R 9 and R 10 are as above defined, comprises:
- R 6 is hydrogen, R 1 , R 2 and X are as above defined, with the proviso that no alkenyl residues are present in G and, in the sugar residue X, R 13 does not represent hydroxy when one of the other substituents of X is hydroxy, into the corresponding 14-bromo derivative, then
- R 1 , R 2 and X are as above defined, with the
- compounds of formula A, defined as under (i) above may be further transformed into other anthracyclines of formula A in which one or both of R 7 and R 8 represents a group of formula COR 9 or SO 2 R, wherein R 9 is as above defined, by reacting a 14-amino derivative of formula A as defined under (i), with the proviso that one or both of R 7 and R 8 represents a hydrogen atom, with an acyl derivative of formula HalCOR 9 or HalSO 2 R 9 , wherein Hal is halogen and R 9 is as above defined, and, if desired, converting the resulting said compound of formula A into a pharmaceutically acceptable salt thereof.
- CHOHCH 2 R 6 comprises reducing a compound of formula A in which R 3 represents COCH 2 R 6 , wherein R 6 is as above defined with the proviso that no additional ketone groups are present in A, and, if desired, converting the resulting said compound of formula A into a pharmaceutically
- R 1 , R 2 and R 3 are as above defined, with the proviso that R 1 , R 2 and R 3 do not represent groups bearing free primary or secondary hydroxy groups, with a sugar
- R 18 represents a suitable leaving group such as a halogen atom, for example a chlorine atom, or an activated ester residue, such as OCOCF 3 or OCO(pNO 2 C 6 H 5 )
- R 19 and R 20 are hydrogen atoms
- R 21 is hydrogen, C 1 -C 4 alkoxy
- an ester residue such as OCOCF 3 or OCO(pNO 2 C 6 H 5 ) or the group NHCOCF 3
- R 22 and R 23 are both hydrogen or one of R 22 or R 23 is hydrogen and the other is an ester residue such as OCOCF 3 or
- R 24 is CH 2 OCOCF 3 or has the same meaning as R 2 , above defined and R 25 represents OCOCF 3 or OCO(pNO 2 C 6 H 5 ), then
- R 7 is as above defined, Hal represents halogen atom and R 17 is an alkoxy residue, preferable ethoxy, and, if desired,
- the compounds of formula A as defined under (i) may be prepared as described in DE-A-2,557, 537, for example by reacting a compound of formula H as above defined, prepared from compound G according to the disclosure of DE-A- 1,197,874 with from 1 to 1.2 equivalents of the appropriate amine of formula NHR 7 R 8 , wherein R 7 and R 8 are as above defined with the proviso that R 7 and R 8 do not represent a group of formula COR 9 , CONR 9 R 10 , CONR 9 COOR 10 or SO 2 R 9 as above defined, in a dry polar solvent such as acetone or
- dimethyl-formamide at a temperature of about 0 to 30°C, preferably at room temperature, for from 4 to 24 hours, and, if desired, converting the resulting said compound of formula A into a pharmaceutically acceptable salt thereof, preferably with anhydrous hydrogen chloride in methanol.
- the compounds of formula A as defined under (ii) may be prepared by reacting a compound of formula A, defined as under (i), with an acyl derivative of formula HalCOR 9 or HalSO 2 R 9 , wherein Hal is halogen and R 9 is as above defined, in dry polar solvent such as acetone or dimethylformamide, at a temperature of about 0 to 30°C, preferably at room temperature, for from 4 to 24 hours.
- dry polar solvent such as acetone or dimethylformamide
- the compounds of formula A as defined under (iii) may be prepared as described in WO 92/10212 and WO 92/02255, for example by reacting an anthracycline as defined under (iii) (l) with derivatives of formula B1 or C1 in an aprotic solvent such as methylene chloride in the presence of an acid catalyst, such as pyridinium p-toluenesulfonate, at a temperature of from 10 to 30°C, preferably at room temperature, and from 3 to 24 hours, and, if desired, converting the resulting said compound of formula A into a pharmaceutically acceptable salt thereof, preferably with anhydrous hydrogen chloride in methanol; or by hydrolyzing the ester derivative with dilute aqueous sodium hydroxide.
- an acid catalyst such as pyridinium p-toluenesulfonate
- the compounds of formula A as defined under (iv) may be prepared by reducing anthracyclines of formula A, as defined under (iv), in water or in one or more organic solvents, depending on the nature of the compound, or by means of microbial reduction.
- water soluble anthracyclines are reduced in water at a pH from 8 to 9, preferably pH 8.5, in the presence of a reducing agent such as sodium borohydride, at a temperature of from 0°C to room temperature and for from 1 to 10 minutes as described in Gaz.Chim.Ital., 114, 185 (1984).
- a reducing agent such as sodium borohydride
- anthracyclines are preferably dissolved in an anhydrous aprotic organic solvent, such as dry tetrahydrofuran, cooled to -50°C, treated with 1.5 equivalents of magnesium bromide etherate and 1.5 equivalents of sodium borohydride for from 5 to 30 minutes, then added dropwise with an anhydrous aprotic organic solvent, such as dry tetrahydrofuran, cooled to -50°C, treated with 1.5 equivalents of magnesium bromide etherate and 1.5 equivalents of sodium borohydride for from 5 to 30 minutes, then added dropwise with an anhydrous aprotic organic solvent, such as dry tetrahydrofuran, cooled to -50°C, treated with 1.5 equivalents of magnesium bromide etherate and 1.5 equivalents of sodium borohydride for from 5 to 30 minutes, then added dropwise with an anhydrous aprotic organic solvent, such as dry tetrahydrofuran, cooled to -50°C, treated with 1.5 equivalents of magnesium bromide etherate
- Microbial reduction of anthracyclines as defined under (iv) may be performed, for example, by using a blocked mutant of Streptomyces peucetius as described in Gaz.Chim.Ital., 114, 185 ( 1984 ) .
- the compounds of formula A as defined under (v) may be prepared as described in GB-A-2238540, for example by reducing the 13-[(4-fluoro) benzenesulfonyl]hydrazone derivative of an anthracycline of formula A, as defined under (v)(1), with sodium cyanoborohydride in an organic solvent, such as toluene or dimethylformamide, at a
- the compounds of formula A may be prepared by condensing an anthracyclinone of formula K, as above defined, by a Koening-Knorr reaction with a halosugar derivative of formula L1 or L2 as above defined, in a dry apolar solvent, such as dry methylene chloride, in the presence of a condensing agent such as mercuric oxide, mercuric bromide, and molecular sieves as described in DE- A-2,525,633.
- a condensing agent such as mercuric oxide, mercuric bromide, and molecular sieves as described in DE- A-2,525,633.
- An alternative procedure comprises condensing an anthracyclinone of formula K with a halosugar derivative of formula L1 or L2 as above defined, in a dry apolar solvent, such as dry methylene chloride, with silver trifluoromethanesulfonate dissolved in ethyl ether, at temperature of from 0 to 25°C, for from 1 to 6 hours, as described in BE-A-842,930.
- a dry apolar solvent such as dry methylene chloride
- the compounds of formula A as defined under (vii) may be prepared by reacting an anthracycline, which has only a primary amino group, with a halo derivative of formula E1 or F1 as above defined, in an organic solvent such as tetrahydrofuran or dimethylformamide, at from 0°C to room temperature, for from 1 to 24 hours.
- the mono-acyl derivative is further treated with a condensing agent such as tetrabutyl ammonium fluoride to afford the cyclic acyl anthracycline.
- anthracyclines of formula A may be analogously prepared starting from known compounds by means of known procedures.
- M2 J.Am. Chem. Soc., 86, 5334, 1964
- the compounds of the present invention are:
- amyloidosis is caused by peculiar monoclonal immunoglobulin light chains which form amyloid fibrilis. These monoclonal light chains are produced by monoclonal plasma cells with a low mitotic index which accounts for their well known insensitivity to chemotherapy. The malignacy of these cells consists in their protidosynthetic activity.
- solubility of existing deposits could be of great benefit for all types of amyloidosis, and in particular for the treatment of Alzheimer's disease.
- AD Alzheimer's Disease
- Dementia pugilistica Dementia pugilistica
- Cerebral amyloid angiopaty amyloid deposition in AD
- cerebral parenchima and vessel walls are associated with neuronal cell loss in cerebral cortex, limbic regions and subcortical nuclei.
- Several studies have shown that selective damage to various neuronal systems and synapse loss in the frontal cortex has been correlated with cognitive decline.
- the pathogenesis and molecular basis of neurodegenerative processes in AD is not known, but the role of ⁇ -amyloid, deposited in brain parinchema and vessel walls has been highlighted by recent report of its
- ⁇ -amyloid has been associated with the fibrilogenic properties of protein.
- Studies with homologous synthetic peptides indicate that hippocampal cells were insensitive to exposure to fresh ⁇ 1-42 solution for 24 h while their viability decreased when neurons were exposed to ⁇ 1-42 previously stored in saline solution for 2-4 days at 37°C to favour the peptide aggregation.
- the relationship between fibrils and neurotoxicity is further supported by recent evidence showing that the soluble form of ⁇ -amyloid is produced in vivo and in vitro during normal cellular metabolism (Hass et al. Nature, 359, 322, 1993) and only when it aggregate in congophilic formation was associated with distrophic nevrites.
- SE spongiform encephalopathy
- PrP Prion protein
- the compounds of the present invention can be used to make medicaments useful to prevent or arrest the
- amyloid proteins progression of diseases caused by amyloid proteins , such as AL amyloidosis, Alzheimer or Down's Syndrome and the like.
- the present invention also includes, within its scope, pharmaceutical compositions comprising one or more compounds of formula A, or pharmaceutically acceptable salts thereof, as active ingredients, in association with pharmaceutically acceptable carriers, excipients or other additives, if necessary.
- pharmaceutical compositions containing a compound of formula A or salts thereof may be prepared in a
- the compounds of the formula A can be administered:
- compositions intended for oral use may be prepared according to any method known in the art for the
- compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, maize starch or alginic acid; binding agents, for example maize starch, gelatin or acacia, and
- lubrificating agents for example magnesium stearate or stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorpion in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl
- Formulation for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose,
- dispersing or wetting agents may be naturally-occurring phosphatides, for example lecithin, or condensation
- alkylene oxide with fatty acids for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol anhydrides, for example polyoxyethylene sorbitan
- the said aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavouring agents, or one or more sweetening agents, such as sucrose or saccharin.
- Oily suspension may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, seseme oil or coconut oil or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beewax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and agents, may also be present.
- the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oils, or a mineral oil for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally- occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan mono-oleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxy ethylene sorbitan monooleate.
- the emulsion may also contain sweetening and flavouring agents. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, sorbitol or sucrose. Such formulations may also contain a
- demulcent demulcent, a preservative and flavouring and coloring agents.
- compositions may be in the form of a sterile injectable aqueous or olagenous suspensions.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent for example, as a solution in 1,3-butane diol.
- acceptable vehicles and solvents that may be employed are water. Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- fatty acids such as oleic acid find use in the preparation of injectables
- Still a further object of the present invention is to provide a method of controlling amyloidosis diseases by administering a therapeutically effective amount of one or more of the active compounds encompassed by the formula A in humans in need of such treatment.
- Daily doses are in the range of about 0.1 to about 50 mg per kg of body weight, according to the activity of the specific compound, the age, weight and conditions of the subject to be treated, the type and the severity of the disease, and the frequency and route of administration; preferably, daily dosage levels are in the range of 5 mg to 2 g.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the
- formulation intended for oral intake may contain from 5 mg to 2 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
- Dosage unit forms will generally contain between from about 5 mg to about 500 mg of the active ingredient.
- the following Examples illustrate the invention without limiting it.
- reaction mixture was concentrated to small volume under reduced pressure, diluted with methylene chloride, cooled at 0°C and treated with a solution of trifluoroacetic anhydride (2 ml) in methylene chloride (10 ml). After 30 minutes the reaction mixture was washed with aqueous 5% sodium hydrogen carbonate and twice with water. The organic phase was concentrated under reduced pressure and flash chromatographed on silica gel using a mixture of methylene chloride/methanol (90:10 v/v) as eluting system to afford the title compound Al that was converted in the
- the title compound A2 was prepared by reacting 14- bromo-4'-iododaunomycin (0.65g, 1mmol) with 3,4- dimethoxybenzylamine (0.3 g, 2mmol) in anhydrous
- Iododoxorubicin hydrochloride (A27, 0.65g, 1mmol) was dissolved in tetrahydrofurane (50ml) and treated with benzophenone
- Anthracycline derivatives of formula A interfere with the self-aggregating activity of ⁇ -amyloid fragment 25-35 and PrP fragment 106-126 by using light scattering
- KTNMKHMAGAAAAGAVVGGLG were synthesized using solid phase chemistry by a 430A Applied Biosystems Instruments and purified by reverse-phase HPLC (Beckman Inst. mod 243) according to Forloni et al., Nature 362: 543, 1993.
- ⁇ -amyloid fragment 25- 35 and PrP 106-126 were dissolved at a concentration of 0.5 to 1 mg/ml (0.4-0.8 mM and 0.2-0.4 mM respectively) in a solution of phosphate buffer pH 5, 10 mM spontaneously aggregate within an hour.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA96062243A UA61875C2 (en) | 1994-09-09 | 1995-05-09 | A medicament for use in the treatment of amyloidosis, an anthracycline and a pharmaceutical composition |
AU35634/95A AU691340C (en) | 1994-09-09 | 1995-09-05 | Anthracycline derivatives |
EP95932665A EP0728138B1 (en) | 1994-09-09 | 1995-09-05 | Anthracycline derivatives |
DK95932665T DK0728138T3 (en) | 1994-09-09 | 1995-09-05 | anthracycline derivatives |
DE69525327T DE69525327T2 (en) | 1994-09-09 | 1995-09-05 | Anthracycline DERIVATIVES |
KR1019960702395A KR100451682B1 (en) | 1994-09-09 | 1995-09-05 | Anthracycline derivatives, preparation methods thereof and pharmaceutical compositions comprising the same |
PL95314269A PL184009B1 (en) | 1994-09-09 | 1995-09-05 | Anthracyclin derivatives |
NZ293243A NZ293243A (en) | 1994-09-09 | 1995-09-05 | Use of optionally halogenated or sulphonated anthracycline (daunomycin, doxorubicia) derivatives to prepare medicaments for treating amyloidosis |
CA002176144A CA2176144C (en) | 1994-09-09 | 1995-09-05 | Anthracycline derivatives for treatment of amyloidosis |
SI9530588T SI0728138T1 (en) | 1994-09-09 | 1995-09-05 | Anthracycline derivatives |
JP50920496A JP4060881B2 (en) | 1994-09-09 | 1995-09-05 | Anthracycline derivatives |
MX9601635A MX9601635A (en) | 1994-09-09 | 1995-09-05 | Anthracycline derivatives. |
AT95932665T ATE212996T1 (en) | 1994-09-09 | 1995-09-05 | ANTHRACYCLINE DERIVATIVES |
US08/635,957 US5744454A (en) | 1994-09-08 | 1995-09-05 | Anthracycline derivatives |
FI961915A FI961915A0 (en) | 1994-09-09 | 1996-05-06 | anthracycline derivatives |
NO19961860A NO310098B1 (en) | 1994-09-09 | 1996-05-08 | Use of anthracycline derivatives, their preparation and pharmaceutical compositions comprising the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9418260.7 | 1994-09-09 | ||
GB9418260A GB9418260D0 (en) | 1994-09-09 | 1994-09-09 | Anthracycline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996007665A1 true WO1996007665A1 (en) | 1996-03-14 |
Family
ID=10761136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/003480 WO1996007665A1 (en) | 1994-09-08 | 1995-09-05 | Anthracycline derivatives |
Country Status (27)
Country | Link |
---|---|
US (1) | US5744454A (en) |
EP (1) | EP0728138B1 (en) |
JP (1) | JP4060881B2 (en) |
KR (1) | KR100451682B1 (en) |
CN (1) | CN1051558C (en) |
AT (1) | ATE212996T1 (en) |
CA (1) | CA2176144C (en) |
CZ (1) | CZ292302B6 (en) |
DE (1) | DE69525327T2 (en) |
DK (1) | DK0728138T3 (en) |
ES (1) | ES2173195T3 (en) |
FI (1) | FI961915A0 (en) |
GB (1) | GB9418260D0 (en) |
HU (1) | HUT75535A (en) |
IL (1) | IL115184A (en) |
MX (1) | MX9601635A (en) |
MY (1) | MY114282A (en) |
NO (1) | NO310098B1 (en) |
NZ (1) | NZ293243A (en) |
PL (1) | PL184009B1 (en) |
PT (1) | PT728138E (en) |
RU (1) | RU2159619C2 (en) |
SI (1) | SI0728138T1 (en) |
TW (1) | TW458954B (en) |
UA (1) | UA61875C2 (en) |
WO (1) | WO1996007665A1 (en) |
ZA (1) | ZA957525B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049433A1 (en) * | 1996-06-26 | 1997-12-31 | Pharmacia & Upjohn S.P.A. | Fluoro labelled anthracyclinone and anthracycline derivatives |
WO1998032754A1 (en) * | 1997-01-27 | 1998-07-30 | Pharmacia & Upjohn S.P.A. | Imino-aza-anthracyclinone derivatives for the treatment of amyloidosis |
WO1999046253A1 (en) * | 1998-03-10 | 1999-09-16 | Pharmacia & Upjohn S.P.A. | Heterocyclyl anthracyclinone derivatives |
US11401339B2 (en) | 2018-08-23 | 2022-08-02 | Seagen Inc. | Anti-TIGIT antibodies |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9416007D0 (en) * | 1994-08-08 | 1994-09-28 | Erba Carlo Spa | Anthracyclinone derivatives |
GB9516349D0 (en) * | 1995-08-09 | 1995-10-11 | Pharmacia Spa | Aza-anthracyclinone derivatives |
US6221614B1 (en) * | 1997-02-21 | 2001-04-24 | The Regents Of The University Of California | Removal of prions from blood, plasma and other liquids |
AU2001286744A1 (en) * | 2000-08-25 | 2002-03-04 | Beth Israel Deaconess Medical Center | Compounds and methods for inhibiting neuronal cell death |
US6624317B1 (en) | 2000-09-25 | 2003-09-23 | The University Of North Carolina At Chapel Hill | Taxoid conjugates as antimitotic and antitumor agents |
US20040191385A1 (en) * | 2003-03-26 | 2004-09-30 | Council Of Scientific And Industrial Research | Composition for stabilizing pink color of fresh large cardamom and a process for stabilizing the pink color of large cardamom |
US7244829B2 (en) * | 2004-11-08 | 2007-07-17 | Gem Pharmaceuticals, Llc | Compositions and processes for preparing 13-deoxy-anthracyclines |
RU2455307C1 (en) * | 2008-04-11 | 2012-07-10 | Тяньцзинь Химэй Байо-Тек Ко., Лтд | Tetracyclic antibiotic anthraquinone derivatives having high activity, synthesis method and use thereof |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2735455A1 (en) * | 1977-08-02 | 1978-02-09 | Farmaceutici Italia | ANTHRACYCLIN ETHER AND METHOD FOR MANUFACTURING THEREOF |
US4077988A (en) * | 1975-01-22 | 1978-03-07 | Societa' Farmaceutici Italia, S.p.A. | Optically active anthracyclinones |
US4107423A (en) * | 1976-06-14 | 1978-08-15 | Societa Farmaceutici Italia S.P.A. | Process for preparing daunomycin and analogues thereof |
US4131649A (en) * | 1976-07-13 | 1978-12-26 | Societa Farmaceutici Italia S.P.A. | Daunorubicin derivatives, their preparation and their use |
US4166848A (en) * | 1976-11-16 | 1979-09-04 | Societa Farmaceutici Italia S.P.A. | Anthracycline derivatives, their preparation and use |
DE3428945A1 (en) * | 1983-08-11 | 1985-02-28 | Farmitalia Carlo Erba S.p.A., Mailand/Milano | 4'-HALOGENANTHRACYCLINGLYCOSIDES, METHOD FOR THE PRODUCTION THEREOF AND THE PHARMACEUTICAL PREPARATION CONTAINING THEM |
DE3520469A1 (en) * | 1984-06-08 | 1985-12-12 | Farmitalia Carlo Erba S.p.A., Mailand/Milano | Anthracyclines, process for their preparation, intermediates and pharmaceutical formulation |
DE3500017A1 (en) * | 1985-01-02 | 1986-07-10 | Farmitalia Carlo Erba S.p.A., Mailand/Milano | 4'-Haloanthracycline esters |
DE3912867A1 (en) * | 1988-04-22 | 1989-11-02 | Erba Carlo Spa | 4-DESMETHOXY-4'-DESOXY-4'-JODOANTHRACYCLINGLYCOSIDE AND METHOD FOR THE PRODUCTION THEREOF |
DE4037693A1 (en) * | 1989-11-29 | 1991-06-06 | Erba Carlo Spa | 13-DEOXO-4'-DEOXY-4'-JODANTHRACYCLINE |
WO1995004538A1 (en) * | 1993-08-06 | 1995-02-16 | Policlinico San Matteo, Istituto Di Ricovero E Cura A Carattere Scientifico Di Diritto Pubblico | Use of 4'-iodo-4'-deoxydoxorubicin for the treatment of amyloidosis |
-
1994
- 1994-09-09 GB GB9418260A patent/GB9418260D0/en active Pending
-
1995
- 1995-03-28 ZA ZA957525A patent/ZA957525B/en unknown
- 1995-05-09 UA UA96062243A patent/UA61875C2/en unknown
- 1995-08-16 TW TW084107341A patent/TW458954B/en active
- 1995-09-05 RU RU96113085/14A patent/RU2159619C2/en not_active IP Right Cessation
- 1995-09-05 DE DE69525327T patent/DE69525327T2/en not_active Expired - Fee Related
- 1995-09-05 AT AT95932665T patent/ATE212996T1/en not_active IP Right Cessation
- 1995-09-05 CN CN95190869A patent/CN1051558C/en not_active Expired - Fee Related
- 1995-09-05 EP EP95932665A patent/EP0728138B1/en not_active Expired - Lifetime
- 1995-09-05 NZ NZ293243A patent/NZ293243A/en not_active IP Right Cessation
- 1995-09-05 CZ CZ19961333A patent/CZ292302B6/en not_active IP Right Cessation
- 1995-09-05 SI SI9530588T patent/SI0728138T1/en unknown
- 1995-09-05 WO PCT/EP1995/003480 patent/WO1996007665A1/en active IP Right Grant
- 1995-09-05 DK DK95932665T patent/DK0728138T3/en active
- 1995-09-05 CA CA002176144A patent/CA2176144C/en not_active Expired - Fee Related
- 1995-09-05 ES ES95932665T patent/ES2173195T3/en not_active Expired - Lifetime
- 1995-09-05 US US08/635,957 patent/US5744454A/en not_active Expired - Fee Related
- 1995-09-05 HU HU9601587A patent/HUT75535A/en unknown
- 1995-09-05 PT PT95932665T patent/PT728138E/en unknown
- 1995-09-05 PL PL95314269A patent/PL184009B1/en not_active IP Right Cessation
- 1995-09-05 KR KR1019960702395A patent/KR100451682B1/en not_active IP Right Cessation
- 1995-09-05 JP JP50920496A patent/JP4060881B2/en not_active Expired - Fee Related
- 1995-09-05 MX MX9601635A patent/MX9601635A/en not_active IP Right Cessation
- 1995-09-06 IL IL11518495A patent/IL115184A/en not_active IP Right Cessation
- 1995-09-08 MY MYPI95002674A patent/MY114282A/en unknown
-
1996
- 1996-05-06 FI FI961915A patent/FI961915A0/en not_active Application Discontinuation
- 1996-05-08 NO NO19961860A patent/NO310098B1/en not_active IP Right Cessation
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4077988A (en) * | 1975-01-22 | 1978-03-07 | Societa' Farmaceutici Italia, S.p.A. | Optically active anthracyclinones |
US4107423A (en) * | 1976-06-14 | 1978-08-15 | Societa Farmaceutici Italia S.P.A. | Process for preparing daunomycin and analogues thereof |
US4131649A (en) * | 1976-07-13 | 1978-12-26 | Societa Farmaceutici Italia S.P.A. | Daunorubicin derivatives, their preparation and their use |
US4166848A (en) * | 1976-11-16 | 1979-09-04 | Societa Farmaceutici Italia S.P.A. | Anthracycline derivatives, their preparation and use |
DE2735455A1 (en) * | 1977-08-02 | 1978-02-09 | Farmaceutici Italia | ANTHRACYCLIN ETHER AND METHOD FOR MANUFACTURING THEREOF |
DE3428945A1 (en) * | 1983-08-11 | 1985-02-28 | Farmitalia Carlo Erba S.p.A., Mailand/Milano | 4'-HALOGENANTHRACYCLINGLYCOSIDES, METHOD FOR THE PRODUCTION THEREOF AND THE PHARMACEUTICAL PREPARATION CONTAINING THEM |
DE3520469A1 (en) * | 1984-06-08 | 1985-12-12 | Farmitalia Carlo Erba S.p.A., Mailand/Milano | Anthracyclines, process for their preparation, intermediates and pharmaceutical formulation |
DE3500017A1 (en) * | 1985-01-02 | 1986-07-10 | Farmitalia Carlo Erba S.p.A., Mailand/Milano | 4'-Haloanthracycline esters |
DE3912867A1 (en) * | 1988-04-22 | 1989-11-02 | Erba Carlo Spa | 4-DESMETHOXY-4'-DESOXY-4'-JODOANTHRACYCLINGLYCOSIDE AND METHOD FOR THE PRODUCTION THEREOF |
DE4037693A1 (en) * | 1989-11-29 | 1991-06-06 | Erba Carlo Spa | 13-DEOXO-4'-DEOXY-4'-JODANTHRACYCLINE |
WO1995004538A1 (en) * | 1993-08-06 | 1995-02-16 | Policlinico San Matteo, Istituto Di Ricovero E Cura A Carattere Scientifico Di Diritto Pubblico | Use of 4'-iodo-4'-deoxydoxorubicin for the treatment of amyloidosis |
Non-Patent Citations (9)
Title |
---|
A. PODESTA ET AL.: "New Anthracycline Glycosides", J. ANTIBIOT., vol. 37, pages 856 - 67 * |
D. GABUZDA ET AL.: "Inhibition of beta-Amyloid Production by Activation of Protein Kinase C", J. NEUROCHEM., vol. 61, pages 2326 - 9 * |
G. MERLINI ET AL.: "Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils", P.N.A.S., vol. 92, no. 7, 28 March 1995 (1995-03-28), pages 2959 - 63 * |
G. MERLINI ET AL.: "New Drug Therapy of Amyloidosis: Resorption of AL-Type Deposits with 4'-Iodo-4'-Deoxydoxorubicin", BLOOD, vol. 86, 1 August 1995 (1995-08-01), pages 855 - 61 * |
H.S.EL KHADEM ET AL.: "Synthesis of epsilon-Rhodomycinone Glycosides", J. MED. CHEM., vol. 20, pages 957 - 60 * |
K. FIELDER, B.G.M. DURIE: "Primary Amyloidosis Associated with Multiple Myeloma", AM. J. MED., vol. 80, pages 413 - 8 * |
P. DOSTERT: "Stereoselectivity of iododoxorubicin reduction in various animal species and humans", XENOBIOTICA, vol. 23, pages 115 - 21 * |
R.A. GAMBETTA ET AL.: "Protein Kinase C Aktivation and Lipid Peroxidation by Doxorubicin Analogues", TUMORI, vol. 75, pages 358 - 61 * |
Y. LEVY ET AL.: "Traitment de l'amylose AL sans myélome", ANN. MED. INTERNE, vol. 139, pages 190 - 3 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049433A1 (en) * | 1996-06-26 | 1997-12-31 | Pharmacia & Upjohn S.P.A. | Fluoro labelled anthracyclinone and anthracycline derivatives |
US6103700A (en) * | 1996-06-26 | 2000-08-15 | Pharmacia & Upjohn S.P.A. | Fluoro labelled anthracyclinone and anthracycline derivatives |
AU726935B2 (en) * | 1996-06-26 | 2000-11-23 | Pharmacia & Upjohn S.P.A. | Fluoro labelled anthracyclinone and anthracycline derivatives |
WO1998032754A1 (en) * | 1997-01-27 | 1998-07-30 | Pharmacia & Upjohn S.P.A. | Imino-aza-anthracyclinone derivatives for the treatment of amyloidosis |
WO1999046253A1 (en) * | 1998-03-10 | 1999-09-16 | Pharmacia & Upjohn S.P.A. | Heterocyclyl anthracyclinone derivatives |
US6316451B1 (en) * | 1998-03-10 | 2001-11-13 | Pharmacia & Upjohn S.P.A. | Heterocyclyl anthracyclinone derivatives |
US11401339B2 (en) | 2018-08-23 | 2022-08-02 | Seagen Inc. | Anti-TIGIT antibodies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU692293B2 (en) | Anthracyclinone derivatives and their use in amyloidosis | |
EP0728138B1 (en) | Anthracycline derivatives | |
WO1996004895A9 (en) | Anthracyclinone derivatives and their use in amyloidosis | |
WO1994020114A1 (en) | Anthracyclines with unusually high activity against cells resistant to doxorubicin and its analogs | |
AU691340C (en) | Anthracycline derivatives | |
EP0843675B1 (en) | Aza-anthracyclinone derivatives | |
AU712411C (en) | Aza-anthracyclinone derivatives | |
MXPA96001269A (en) | Derivatives of antraciclinona and its use in amiloido | |
WO1995016693A2 (en) | 4'-o-sulfonyl-anthracycline derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95190869.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995932665 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 293243 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08635957 Country of ref document: US Ref document number: 961915 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1996-1333 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2176144 Country of ref document: CA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1995932665 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1996-1333 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995932665 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1996-1333 Country of ref document: CZ |